Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies

Florence Gunawan, Elizabeth George and Adam Roberts
Geelong University Hospital, Barwon Health, Geelong, Victoria, Australia

Summary

Immune checkpoint inhibitors are the mainstay of treatment for advanced melanoma, and their use is being increasingly implicated in the development of autoimmune endocrinopathies. We present a case of a 52-year-old man with metastatic melanoma on combination nivolumab and ipilimumab therapy who developed concurrent hypophysitis, type 1 diabetes mellitus (T1DM) and diabetes insipidus. He presented prior to third cycle of combination treatment with a headache, myalgias and fatigue. Biochemistry and MRI pituitary confirmed anterior pituitary dysfunction with a TSH: 0.02 mU/L (0.5–5.5 mU/L), fT4: 5.2 pmol/L (11–22 pmol/L), fT3: 4.0 pmol/L (3.2–6.4 pmol/L), cortisol (12:00 h): <9 nmol/L (74–286 nmol/L), FSH: 0.7 IU/L (1.5–9.7 IU/L), LH: <0.1 IU/L (1.8–9.2 IU/L), PRL: 1 mIU/L (90–400 mIU/L), SHBG: 34 nmol/L (19–764 nmol/L) and total testosterone: <0.4 nmol/L (9.9–27.8 nmol/L). High-dose dexamethasone (8 mg) was administered followed by hydrocortisone, thyroxine and topical testosterone replacement. Two weeks post administration of the third cycle, he became unwell with lethargy, weight loss and nocturia. Central diabetes insipidus was diagnosed on the basis of symptoms and sodium of 149 mmol/L (135–145 mmol/L). Desmopressin nasal spray was instituted with symptom resolution and normalization of serum sodium. Three weeks later, he presented again polyuric and polydipsic. His capillary glucose was 20.8 mmol/L (ketones of 2.4 mmol), low C-peptide 0.05 nmol/L (0.4–1.5 nmol/L) and HbA1c of 7.7%. T1DM was suspected, and he was commenced on an insulin infusion with rapid symptom resolution. Insulin antibodies glutamic acid decarboxylase (GAD), insulin antibody-2 (IA-2) and zinc transporter-8 (ZnT8) were negative. A follow-up MRI pituitary revealed findings consistent with recovering autoimmune hypophysitis. Immunotherapy was discontinued based on the extent of these autoimmune endocrinopathies.

Learning points:

• The most effective regime for treatment of metastatic melanoma is combination immunotherapy with nivolumab and ipilimumab, and this therapy is associated with a high incidence of autoimmune endocrinopathies.
• Given the high prevalence of immune-related adverse events, the threshold for functional testing should be low.
• Traditional antibody testing may not be reliable to identify early-onset endocrinopathy.
• Routine screening pathways have yet to be adequately validated through clinical trials.

Background

Immunotherapy has gained popularity as the new novel agent in cancer treatment. Activation of the immune system however has resulted in many autoimmune adverse effects. Our patient had diabetes insipidus, which is a rare complication. To our knowledge, this is also the first case in the literature reporting concurrent hypophysitis, type 1...
diabetes mellitus and diabetes insipidus in a patient on combination immunotherapy for metastatic melanoma.

**Presentation, investigation and initial management**

A 52-year-old firefighter, with stage IV metastatic melanoma was initiated on combination checkpoint inhibitor therapy (dosing regimen: ipilimumab 3 mg/kg three weekly, nivolumab 1 mg/kg three weekly) after two melanoma deposits had been resected from his bowel. He had an initial small bowel resection and a follow-up 18FDG PET-CT performed six months later found a mesenteric splanchnic mass with malignant ascites. There was no skin or CNS involvement, and the primary tumor remained unknown. The combination immune checkpoint inhibitor was the primary treatment regimen.

He was not on any regular medications and had been fit and well prior to the discovery of his melanoma. Full blood counts, biochemistry and thyroid function were within normal limits prior to initiation of therapy.

He presented to the emergency department one week following the second cycle of therapy with an abrupt onset of ‘the worst ever headache’ and transient blurred vision. He was discharged the same day, and his headache resolved over the next week.

Clinical evaluation prior to the third cycle of therapy found him to be hypothyroid with undetectable cortisol. He reported joint aches and low energy and was admitted to hospital for further endocrinologist evaluation. Examination revealed delayed deep tendon reflexes and blood pressure of 112/70 mmHg, with no evidence of postural hypotension. Heart rate was 80 beats per minute, temperature of 36.2°C. He had full visual fields; hence, no neuroophthalmology consult or computerized static perimetry was done.

His biochemistry confirmed anterior pituitary dysfunction (TSH: 0.02 mU/L (0.5–5.5 mU/L), fT4: 5.2 pmol/L (11–22 pmol/L), fT3: 4.0 pmol/L (3.2–6.4 pmol/L), cortisol (12:00 h): <9 nmol/L (74–286 nmol/L), FSH: 0.7 IU/L (1.5–9.7 IU/L), LH: <0.1 IU/L (1.8–9.2 IU/L), PRL: 1 mIU/L (90–400 mIU/L), SHBG: 34 nmol/L (19–764 nmol/L) and total testosterone: <0.4 nmol/L (9.9–27.8 nmol/L). The free testosterone was not measurable. ACTH and GH were not initially tested. Blood glucose was 5.2 mmol/L and Na was 143 mmol/L (136–145 mmol/L). Full blood examination (FBE), other electrolytes and liver function tests were normal.

An MRI of the brain (Fig. 1) showed mild diffuse enlargement of the pituitary with contrast enhancement of the pituitary stalk and posterior pituitary. The anterior pituitary was heterogenous with a cystic component suggestive of a possible hemorrhage. There was no encroachment onto the optic chiasm. The differential diagnosis for this appearance included hypophysitis or metastatic melanoma.

A late attempt to salvage and preserve pituitary function from autoimmune destruction was made by using high-dose IV dexamethasone 8 mg twice daily. Decision was made to switch to oral hydrocortisone 20/10 mg maintenance therapy the next day on the basis of late presentation of the disease and the absence of headache. Thyroxine and topical testosterone were commenced a week later. After some deliberation, the
third cycle of combination immunotherapy was given two weeks after the onset of hypophysitis on the basis that there was no ongoing toxicity. Decision to continue with the third cycle was based on malignant cells in the peritoneal fluid by the treating oncologist.

Two weeks after recommencement, he became clinically unwell with lethargy, nausea, weight loss and significant polyuria and nocturia. Central diabetes insipidus was diagnosed on the basis of symptoms in the context of pituitary insult and sodium of 149 mmol/L (135–145 mmol/L). No formal 24-h urine volume quantification, serum or urine osmolality performed at that stage. Desmopressin nasal spray, twice at night, was instituted with relief of symptoms and normalization of his sodium. An attempt at lowering the dose resulted in a return of symptoms and hypernatremia.

Three weeks after his immunotherapy cycle, he presented again polyuric and with polydipsia despite good compliance with his desmopressin. Nausea and vomiting was also a feature. He was admitted into hospital and was found to have a capillary glucose of 20.8 mmol/L (ketones of 2.4 mmol). His C-peptide was 0.05 nmol/L (0.4–1.5 nmol/L), proinsulin was undetectable at <3.1 pmol/L (<13.3 pmol/L) and HbA1c was 7.7%. His bicarbonate level was 24 mmol/L (22–32 mmol/L). Type 1 diabetes mellitus was suspected, and he was commenced on an insulin infusion for glucose stabilization. The nausea resolved quickly. Insulin antibodies including glutamic acid decarboxylase (GAD), insulin antibody-2 (IA-2) and zinc transporter-8 (ZnT8) were negative. He continued to require a relatively high dose of insulin in the form of a basal bolus regimen of Lantus 22 units daily with NovoRapid three times a day with meals, dosed as per carbohydrate intake with insulin-to-carbohydrate ratio (ICR) of 1:7.5 and insulin sensitivity factor (ISF) of 1:2.4. His weight was 89 kg.

**Outcome and follow-up**

A follow-up gadolinium-enhanced MRI of the pituitary (Fig. 2) revealed resolution of the pituitary swelling. The anterior pituitary exhibited no post-contrast enhancement while the posterior pituitary enhanced normally. The findings were considered consistent with recovering autoimmune hypophysitis. He was continued on maintenance dose of hydrocortisone 20/10 mg daily, thyroxine, testosterone replacement, desmopressin nasal spray and insulin.

Immunotherapy was discontinued based on the extent of these toxicities. Immunotherapy was discontinued based on the extent of toxicities. The patient remains on insulin, desmopressin and hormone replacement.

**Discussion**

Immune checkpoint inhibitor therapy has outperformed targeted molecular therapies in the treatment of advanced melanoma. Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is a protein receptor expressed on T-cells that downregulates the immune system. Ipilimumab is a monoclonal antibody that upregulates anti-tumor immunity by blocking CTLA-4 receptors allowing antigen-presenting cells to recognize tumor cells as targets. Ipilimumab was the first agent to be associated with improvement in overall survival in patients with metastatic melanoma (1).
The binding of programmed cell death-1 (PD-1) on T-cells to PD-1L on cancer cells also downregulates the immune system. Nivolumab is a monoclonal antibody against the PD1 receptor, which functions to inhibit the downregulation of the immune system toward tumor cells.

The inherent risk of these therapies is autoimmune disease from unrestrained T cell activation. Autoimmune endocrinopathies such as thyroid dysregulation, hypophysitis, adrenal insufficiency and T1DM have been described in the literature. In ipilimumab-treated metastatic melanoma, the incidence of hypophysitis varies from 5 to 17% with a time to onset between 2 and 4 months, however, more delayed presentations may occur (2, 3, 4, 5). The incidence of hypophysitis with nivolumab monotherapy is lower at <1%, (compared to ipilimumab) and the median time to onset is 4.9 months (6). Central hypothyroidism is perhaps the most common but multiple anterior pituitary hormone deficiencies do occur (5). Diabetes insipidus on the other hand is rare (4, 5). Inflammatory process causing pituitary destruction commonly results in anterior pituitary dysfunction, whereas posterior pituitary function often remains normal. The cause for this is unclear. We postulate that the structural difference of the anterior and posterior pituitary gland could potentially account for this. Anterior pituitary gland is connected to the hypothalamus through a vascular hypothalamus–hypophyseal portal system. It also synthesizes and secretes hormones. The posterior pituitary gland is made of nerve bundle as an extension of the hypothalamus and it only stores and secretes but does not synthesize hormones. We think that the vascularity of the anterior pituitary gland is less likely to be the etiology of diabetes given the low proinsulin and C-peptide level.

Combination therapy has been shown to significantly increase progression-free survival than treatment with ipilimumab alone (9). Immune-related side effects are compounded in combination therapy. The incidence of type 1 diabetes doubles to 1.5% and the median time to onset is faster at 2.2 months.

Hypophysitis occurs much more commonly in patients treated with combination immunotherapies than either therapy alone. Studies demonstrate an incidence of 9–12% in combination therapy, compared to <1% in nivolumab monotherapy and 7% in ipilimumab monotherapy. The incidence of hypophysitis further increases with the number of doses of ipilimumab or nivolumab in the combination therapy (10). The median time to onset of hypophysitis is also faster in combination therapy at 2.7 months. A variable number of patients with hypophysitis recover some anterior pituitary function; however, the time to recovery is unpredictable. The rate of discontinuation of therapy due to adverse effects was also higher in combination therapy (9, 10).

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Patient consent
Informed consent has been obtained from the patient for publication of the submitted article (file attached).

Author contribution statement
Florence Gunawan: Consolidated information including investigations results and treatment; writing up case report. Elizabeth George: Writing up case report. Adam Roberts: Treating physician; writing and supervising case report.

References
2 Horvat TZ, Adel NG, Dang TO, Montaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D’Angelo SP, Woo KM, et al. Immune-related
adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Centre. *Journal of Clinical Oncology* 2015 **33** 3193–3198. (https://doi.org/10.1200/JCO.2015.60.8448)


Received in final form 20 December 2017
Accepted 16 January 2018